Business
ALR Technologies Announces Completion of Pivotal Non-Inferiority Study on the GluCurve Pet CGM
ALR Technologies Announces Completion of Pivotal Non-Inferiority Study on the GluCurve Pet CGM.
About this update from Alr Technologies Sg Ltd.
[{"type":"text","content":"\n SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today announced successful results from the conclusion of the non-inferiority study conducted on the GluCurve Pet CGM which was previously announced on February 10, 2022 and February 28, 2022. GluCurve is the first of its kind Continuous Glucose Monitor (CGM) specifically for diabetic cats and dogs. Notable findings from the study: Utilizing a chemistry analyzer as the baseline, the GluCurve Pet CGM was more accurate than the leading Blood Glucose Meter (BGM) for animals 47.8% of the time.100% of the GluCurve Pet CGM readings paired to the chemistry analyzer reference values were within ±20%, compared to 86.9% from the animal BGMThe GluCurve Pet CGM’s average deviation from the baseline was 9.7% compared to 8.2% from the animal BGM.No clinically significant differences were found when comparing the GluCurve Pet CGM to the chemistry analyzer or leading animal BGM.GluCurve displayed otherwise unavailable data on insulin injection times, eating habits, activity, and stress seen through changes in glucose on a day-to-day basis. Dr. Imperato, lead veterinarian in the study commented, “The GluCurve Pet CGM plugs a long-standing gap in managing veterinary diabetic patients; not only will veterinarians finally receive effortlessly accurate data, the patients will live longer too.” “The non-inferiority study further demonstrates the significant need for GluCurve in veterinary medicine. The in-home data collected is invaluable to veterinarians and by analyzing and organizing it into effective patient management it greatly reduces the effort and time needed by clinicians to treat diabetic pets,” said Sidney Chan, Chairman and CEO of ALR Technologies. “Now that we have the successful results of the non-inferiority study, a MOU for manufacturing with a definitive agreement in the works, and conducted preliminary discussions with the leading animal health pharmaceutical companies, we are well positioned to start realizing the full potentials of ALRT. We will now focus our attention on completing a partnership agreement in the near future to commercially launch GluCurve Pet CGM in a meaningful way in Q3 2022.” About ALR Technologie...